1014 GMT - Haleon's earnings-per-share beat signals an turning point, Barclays analysts say in a note. The British consumer-health giant's historical lack of EPS delivery has been a key investor complaint which should ease now after its 2H topped consensus by 6%, Barclays says. "Given recent strength in Haleon's share price we could see some profit taking first thing this morning, but the robust topline and EPS delivery confirm our thesis that Haleon is establishing a track record as a steady compounder," the analysts say. Haleon's 2025 guidance is in line with expectations, but its 2H weighting comes as a surprise, they add. Shares are down 3.1% at 38.33 pounds. (helena.smolak@wsj.com)
(END) Dow Jones Newswires
February 27, 2025 05:14 ET (10:14 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。